

## SUPPLEMENTARY DATA

**Supplementary Table 1.** Hazard ratio for the primary cardiovascular endpoints for pioglitazone (PROactive plus IRIS), GLP-1 RAs (liraglutide plus semaglutide) and empagliflozin.

### [A] Pioglitazone:

<u>PROactive + IRIS</u>	<u>Hazard Ratio</u>	<u>95% CI</u>
Stroke	0.82	0.692-0.99
MI	0.74	0.60-0.91
Mortality	0.92	0.79-1.09
3-POINT MACE	0.82	0.73-0.92

### [B] Long Acting (≥24 hours): GLP-1 RAs:

<u>SUSTAIN+LEADER</u>	<u>Hazard Ratio</u>	<u>95% CI</u>
Stroke	0.82	0.69-0.99
MI	0.84	0.73-0.97
Mortality	0.87	0.77-0.99
3-POINT MACE	0.85	0.78-0.94

### [C] Empagliflozin

<u>EMPA REG OUTCOME</u>	<u>Hazard Ratio</u>	<u>95% CI</u>
Stroke	1.24	0.92-1.67
MI	0.92	0.75-1.13
Mortality	0.68	0.57-0.82
3-POINT MACE	0.86	0.74-0.99